Veracyte, Inc.

212 articles with Veracyte, Inc.

• Veracyte to Present at the 21st Annual Needham Growth Conference

  1/9/2019

  Veracyte, Inc. today announced that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to present at the 21st Annual Needham Growth Conference in New York City on Tuesday, January 15, 2019 at 8:40 a.m. EST (5:40 a.m. PST).

• 

  Let's Make a Deal: Veracyte & J&J, Vertex & Arbor, Esperion & Daiichi Sankyo and More

  1/4/2019

  With the holidays over and the JP Morgan Healthcare Conference next week, companies were clearly revving their engines, ready to race into the new year. Here’s a roundup of some of the top deals that were announced today.

• Veracyte Announces Strategic Collaboration with Johnson & Johnson Innovation in Battle Against Lung Cancer

  1/3/2019

  Veracyte, Inc. (“Veracyte”) (Nasdaq: VCYT) announced today that it has entered into a long-term strategic collaboration with Johnson & Johnson Innovation LLC* and the Lung Cancer Initiative at Johnson & Johnson to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages, when the disease is most treatable.

• Veracyte to Present at the 37th Annual J.P. Morgan Healthcare Conference

  1/2/2019

  Veracyte, Inc. today announced that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 11:30 a.m. PST (2:30 p.m. EST) followed by a question and answer (Q&A) session at 12:00 p.m. PST (3:00 p.m. EST).

• Veracyte Announces Expansion of Envisia Genomic Classifier Early Access Program

  12/5/2018

  Veracyte, Inc. (Nasdaq: VCYT) today announced that 20 medical centers across the United States are now offering the Envisia Genomic Classifier through an Early Access Program (EAP) to patients who are undergoing evaluation for interstitial lung diseases (ILD), including idiopathic pulmonary fibrosis (IPF

• Veracyte to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum

  11/9/2018

  Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15, 2018, at 9:00 a.m. Eastern Time (ET).

• Veracyte Announces Publication of Data Demonstrating “Real World” Performance of Afirma GSC in Thyroid Cancer Diagnosis

  11/8/2018

  Veracyte, Inc. announced today the publication of “real world” data showing that the Afirma® Genomic Sequencing Classifier (GSC) enables even more patients to avoid unnecessary surgery in thyroid cancer diagnosis compared to the company’s flagship, original Afirma Gene Expression Classifier (GEC). The findings are published online in Endocrine Practice, the journal of the American Association of Clinical Endocrinologists.

• Veracyte Announces Third Quarter 2018 Financial Results

  10/29/2018

  Revenue Grew 34 Percent and Genomic Test Volume Increased 23 Percent

• Veracyte to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results on Monday, October 29, 2018

  10/15/2018

  Veracyte, Inc. (Nasdaq: VCYT) will release its third quarter 2018 financial results after the close of market on Monday, October 29, 2018

• Veracyte Announces Presentation of “Real World” Clinical Utility Data at CHEST 2018 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis

  10/9/2018

  Preliminary data from ongoing, three-year registry study demonstrate that reduction in potentially harmful invasive procedures extends for first 12 months post-test

• Veracyte Announces Presentation of Data Confirming Envisia Genomic Classifier’s Ability to Improve Diagnosis of Idiopathic Pulmonary Fibrosis

  10/8/2018

  Veracyte, Inc. (Nasdaq: VCYT) announced the presentation of data demonstrating that the Envisia Genomic Classifier can help physicians more confidently diagnose interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF), without the need for surgery.

• Veracyte Announces that New Data from Multiple Studies Demonstrate “Real World” Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis

  10/6/2018

  Study findings reported at the American Thyroid Association Annual Meeting

• Veracyte to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

  9/27/2018

  Veracyte, Inc. today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the 2018 Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, 2018, at 1:05 p.m. Eastern Time (ET).

• Veracyte Announces Multiple Studies to Be Presented at ATA Annual Meeting Demonstrating “Real World” Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis

  9/26/2018

  Veracyte Announces Multiple Studies to Be Presented at ATA Annual Meeting Demonstrating “Real World” Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis

• Veracyte to Present at the Canaccord Genuity 38th Annual Growth Conference

  7/30/2018

  Veracyte, Inc. announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the Canaccord Genuity 38th Annual Growth Conference on Thursday, August 9, 2018 at 11:30 a.m. Eastern Time in Boston.

• Veracyte Announces Pricing of Public Offering of 5,000,000 Shares of Common Stock At $10.25 Per Share

  7/26/2018

  Veracyte, Inc. announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $10.25 per share.

• Veracyte Announces Second Quarter 2018 Financial Results

  7/23/2018

  Revenue up 24% to $22.8 Million Compared to Second Quarter 2017

• Veracyte to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results on Monday, July 23, 2018

  7/9/2018

  Veracyte, Inc. announced today that it will report its second quarter 2018 financial results after the close of market on Monday, July 23, 2018.

• Veracyte Chairman and CEO to Speak at MedCity CONVERGE

  7/2/2018

  ​Veracyte, Inc. today announced that Bonnie Anderson, chairman and chief executive officer, will speak at the 2018 MedCity CONVERGE conference in a session entitled, “Early Diagnosis Through Predictive Biomarkers, Noninvasive Testing.”

• Veracyte to Present at the William Blair 38th Annual Growth Stock Conference

  5/30/2018

  Veracyte, Inc. announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the William Blair 38th Annual Growth Stock Conference.